Core Laboratories (NYSE: CLB) reported Q2 EPS of $0.18, $0.02 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $118.7 million versus the consensus estimate of $119.38 million.

GUIDANCE:

Core Laboratories sees Q3 2021 EPS of $0.19-$0.21, versus the consensus of $0.23.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.